Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Cortexyme reports Q3 EPS (73c), consensus (62c) » 16:35
11/12/20
11/12
16:35
11/12/20
16:35
CRTX

Cortexyme

$47.20 /

-0.49 (-1.03%)

Cash, cash equivalents,…

Cash, cash equivalents, and short and long-term marketable securities as of September 30, 2020, were $197.9 million, and includes approximately $117.6 million of net proceeds raised in Cortexyme's private placement offering completed in February 2020. Cortexyme expects current cash, cash equivalents and marketable securities will be sufficient to fund its operating and capital expenditures through 2022 and the completion of the GAIN Trial. "We are pleased with the strong participation in the GAIN Trial and deeply appreciate the support and dedication of patients and the medical community as we approach the interim analysis before the end of this year," said Casey Lynch, Cortexyme's CEO. "With a strong balance sheet and a talented team, we remain confident that Cortexyme is well positioned to advance new therapeutic options for patients with Alzheimer's and other degenerative diseases."

ShowHide Related Items >><<
CRTX Cortexyme
$47.20 /

-0.49 (-1.03%)

CRTX Cortexyme
$47.20 /

-0.49 (-1.03%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
CRTX Cortexyme
$47.20 /

-0.49 (-1.03%)

  • 06
    Feb
CRTX Cortexyme
$47.20 /

-0.49 (-1.03%)

Conference/Events
Cortexyme participates in a conference call with Jefferies » 12:45
10/30/20
10/30
12:45
10/30/20
12:45
CRTX

Cortexyme

$49.59 /

-0.81 (-1.61%)

Healthcare Analyst Amin…

Healthcare Analyst Amin holds a conference call with CEO Lynch and CFO Lowe on October 30 at 1 pm hosted by Jefferies.

ShowHide Related Items >><<
CRTX Cortexyme
$49.59 /

-0.81 (-1.61%)

CRTX Cortexyme
$49.59 /

-0.81 (-1.61%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
CRTX Cortexyme
$49.59 /

-0.81 (-1.61%)

  • 06
    Feb
CRTX Cortexyme
$49.59 /

-0.81 (-1.61%)

Conference/Events
Cortexyme participates in a conference call with Jefferies » 09:59
10/30/20
10/30
09:59
10/30/20
09:59
CRTX

Cortexyme

$50.37 /

-0.03 (-0.06%)

Healthcare Analyst Amin…

Healthcare Analyst Amin holds a conference call with CEO Lynch and CFO Lowe on October 30 at 1 pm hosted by Jefferies.

ShowHide Related Items >><<
CRTX Cortexyme
$50.37 /

-0.03 (-0.06%)

CRTX Cortexyme
$50.37 /

-0.03 (-0.06%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
CRTX Cortexyme
$50.37 /

-0.03 (-0.06%)

  • 06
    Feb
CRTX Cortexyme
$50.37 /

-0.03 (-0.06%)

Over a month ago
Hot Stocks
Cortexyme announces GAIN trial of atuzaginstat in AD exceeds enrollment target » 08:03
09/24/20
09/24
08:03
09/24/20
08:03
CRTX

Cortexyme

$48.15 /

-1.81 (-3.62%)

Cortexyme announced that…

Cortexyme announced that its GAIN Trial for Alzheimer's disease, AD,has exceeded its enrollment target of 570 patients. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat, COR388, Cortexyme's lead investigational medicine, in patients with mild to moderate AD. The GAIN Trial's protocol includes an interim analysis on the study's co-primary cognitive and global endpoints after approximately 300 patients reach 24 weeks of treatment, and this interim analysis is expected to occur before year-end 2020. Top-line results of the GAIN Trial's final analysis, to be performed once all study subjects complete the one-year study, are expected in Q4 2021. "The GAIN Trial is an important study of a potential new approach to addressing Alzheimer's. We are pleased the trial has reached this milestone on schedule, and we look forward to completing the trial's interim analysis before year-end 2020," said Michael Detke, M.D., Ph.D., Cortexyme's Chief Medical Officer. "The significant need for new therapeutic options for Alzheimer's patients grows every day, and we are encouraged by the body of evidence supporting atuzaginstat's mechanism of action, which is 'upstream' of other approaches."

ShowHide Related Items >><<
CRTX Cortexyme
$48.15 /

-1.81 (-3.62%)

CRTX Cortexyme
$48.15 /

-1.81 (-3.62%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
CRTX Cortexyme
$48.15 /

-1.81 (-3.62%)

  • 06
    Feb
CRTX Cortexyme
$48.15 /

-1.81 (-3.62%)

Hot Stocks
Cortexyme receives atuzaginstat-related patent from USPTO » 08:06
08/27/20
08/27
08:06
08/27/20
08:06
CRTX

Cortexyme

$42.87 /

+0.43 (+1.01%)

Cortexyme announced that…

Cortexyme announced that the U.S. Patent and Trademark Office, or USPTO, issued U.S. Patent No. 10,730,826 relating to Cortexyme's lead small molecule, atuzaginstat, or COR388. Cortexyme's '826 patent provides additional composition of matter protection for atuzaginstat and gingipain inhibitors, with additional claims pending in related applications. The patent is expected to provide patent protection for atuzaginstat through September 2037, not including a possible patent term extension of up to five years as provided under the Drug Price Competition and Patent Restoration Act.

ShowHide Related Items >><<
CRTX Cortexyme
$42.87 /

+0.43 (+1.01%)

CRTX Cortexyme
$42.87 /

+0.43 (+1.01%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
CRTX Cortexyme
$42.87 /

+0.43 (+1.01%)

  • 06
    Feb
CRTX Cortexyme
$42.87 /

+0.43 (+1.01%)

Options
Eight new option listings on August 26th » 08:30
08/26/20
08/26
08:30
08/26/20
08:30
ALVR

AlloVir

$33.18 /

+0.53 (+1.62%)

, CRTX

Cortexyme

$42.44 /

+0.16 (+0.38%)

, CVAC

CureVac

$63.09 /

+1.12 (+1.81%)

, FLGT

Fulgent Genetics

$45.95 /

+0.26 (+0.57%)

, NOVA

Sunnova Energy

$24.97 /

+1.445 (+6.14%)

, PROF

Profound Medical

$14.50 /

-0.03 (-0.21%)

, TFFP

TFF Pharmaceuticals

$12.80 /

-0.53 (-3.98%)

, VITL

Vital Farms

$38.21 /

-1.42 (-3.58%)

New option listings for…

New option listings for August 26th include AlloVir Inc (ALVR), Cortexyme Inc (CRTX), CureVac NV (CVAC), Fulgent Genetics (FLGT), Sunnova Energy International Inc (NOVA), Profound Medical Corporation (PROF), TFF Pharmaceuticals Inc (TFFP), and Vital Farms Inc (VITL).

ShowHide Related Items >><<
TFFP TFF Pharmaceuticals
$12.80 /

-0.53 (-3.98%)

NOVA Sunnova Energy
$24.97 /

+1.445 (+6.14%)

FLGT Fulgent Genetics
$45.95 /

+0.26 (+0.57%)

CVAC CureVac
$63.09 /

+1.12 (+1.81%)

CRTX Cortexyme
$42.44 /

+0.16 (+0.38%)

ALVR AlloVir
$33.18 /

+0.53 (+1.62%)

08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
08/24/20
Fly Intel: Top five analyst initiations
08/24/20 SVB Leerink
AlloVir initiated with an Outperform at SVB Leerink
08/24/20 JPMorgan
AlloVir initiated with an Overweight at JPMorgan
CRTX Cortexyme
$42.44 /

+0.16 (+0.38%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
CVAC CureVac
$63.09 /

+1.12 (+1.81%)

FLGT Fulgent Genetics
$45.95 /

+0.26 (+0.57%)

08/20/20
Fly Intel: Top five analyst initiationsNewPage
08/20/20 Oppenheimer
Oppenheimer bullish on Fulgent Genetics, initiates with an Outperform
08/19/20 Oppenheimer
Fulgent Genetics initiated with an Outperform at Oppenheimer
08/17/20 Piper Sandler
Fulgent Genetics price target raised to $73 from $68 at Piper Sandler
NOVA Sunnova Energy
$24.97 /

+1.445 (+6.14%)

07/31/20 Roth Capital
Sunnova Energy price target raised to $33 from $28 at Roth Capital
07/27/20 Roth Capital
Sunnova Energy price target raised to $28 from $22 at Roth Capital
07/22/20 BofA
Sunnova Energy upgraded to Buy from Neutral at BofA
07/13/20 KeyBanc
KeyBanc upgrades Sunrun to Overweight on Vivint merger
PROF Profound Medical
$14.50 /

-0.03 (-0.21%)

08/07/20 Alliance Global Partners
Profound Medical price target raised to $18 from $15 at Alliance Global Partners
07/31/20 Raymond James
Profound Medical price target raised to C$43 from C$38 at Raymond James
06/26/20 Raymond James
Profound Medical price target raised to C$38 from C$35 at Raymond James
04/07/20 Mackie
Profound Medical downgraded to Hold from Buy at Mackie
TFFP TFF Pharmaceuticals
$12.80 /

-0.53 (-3.98%)

08/17/20 Maxim
TFF Pharmaceuticals price target raised to $18 from $12 at Maxim
08/14/20 Roth Capital
TFF Pharmaceuticals price target raised to $18 from $15 at Roth Capital
07/08/20 Maxim
TFF Pharmaceuticals initiated with a Buy at Maxim
02/27/20 Roth Capital
TFF Pharmaceuticals initiated with a Buy at Roth Capital
VITL Vital Farms
$38.21 /

-1.42 (-3.58%)

08/26/20 Jefferies
Vital Farms initiated with a Buy at Jefferies
08/25/20 Morgan Stanley
Morgan Stanley sees high expectations for Vital Farms, starts at Equal Weight
08/25/20 Stifel
Vital Farms initiated with a Buy at Stifel
08/25/20 Credit Suisse
Vital Farms initiated with a Neutral at Credit Suisse
TFFP TFF Pharmaceuticals
$12.80 /

-0.53 (-3.98%)

NOVA Sunnova Energy
$24.97 /

+1.445 (+6.14%)

FLGT Fulgent Genetics
$45.95 /

+0.26 (+0.57%)

CRTX Cortexyme
$42.44 /

+0.16 (+0.38%)

  • 14
    Aug
  • 14
    Aug
  • 31
    Jul
  • 30
    Jul
  • 16
    Jul
  • 01
    Jul
  • 06
    Feb
  • 22
    Jan
  • 14
    Nov
TFFP TFF Pharmaceuticals
$12.80 /

-0.53 (-3.98%)

FLGT Fulgent Genetics
$45.95 /

+0.26 (+0.57%)

CVAC CureVac
$63.09 /

+1.12 (+1.81%)

ALVR AlloVir
$33.18 /

+0.53 (+1.62%)

Over a quarter ago
Conference/Events
JMP Securities to hold a virtual forum » 04:55
08/20/20
08/20
04:55
08/20/20
04:55
ACAD

Acadia

$38.91 /

-0.745 (-1.88%)

, AQST

Aquestive Therapeutics

$8.17 /

+0.09 (+1.11%)

, CNCE

Concert Pharmaceuticals

$10.10 /

-0.09 (-0.88%)

, CRTX

Cortexyme

$44.00 /

-0.65 (-1.46%)

, KRTX

Karuna Therapeutics

$82.23 /

-0.56 (-0.68%)

, NERV

Minerva

$3.44 /

-0.005 (-0.15%)

, TRVN

Trevena

$1.97 /

-0.12 (-5.76%)

, ZGNX

Zogenix

$23.90 /

-0.11 (-0.46%)

CNS Virtual Forum will be…

CNS Virtual Forum will be held on August 19-20.

ShowHide Related Items >><<
ZGNX Zogenix
$23.90 /

-0.11 (-0.46%)

TRVN Trevena
$1.97 /

-0.12 (-5.76%)

NERV Minerva
$3.44 /

-0.005 (-0.15%)

KRTX Karuna Therapeutics
$82.23 /

-0.56 (-0.68%)

CRTX Cortexyme
$44.00 /

-0.65 (-1.46%)

CNCE Concert Pharmaceuticals
$10.10 /

-0.09 (-0.88%)

AQST Aquestive Therapeutics
$8.17 /

+0.09 (+1.11%)

ACAD Acadia
$38.91 /

-0.745 (-1.88%)

ACAD Acadia
$38.91 /

-0.745 (-1.88%)

07/27/20 Canaccord
Acadia pullback a buying opportunity, says Canaccord
07/21/20 Oppenheimer
Acadia price target lowered to $42 from $53 at Oppenheimer
07/21/20 RBC Capital
Acadia price target lowered to $55 from $61 at RBC Capital
07/21/20 Citi
Acadia price target lowered to $63 from $69 at Citi
AQST Aquestive Therapeutics
$8.17 /

+0.09 (+1.11%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
CNCE Concert Pharmaceuticals
$10.10 /

-0.09 (-0.88%)

03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
01/22/20 Truist
Concert Pharmaceuticals price target raised to $30 from $25 at SunTrust
CRTX Cortexyme
$44.00 /

-0.65 (-1.46%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
KRTX Karuna Therapeutics
$82.23 /

-0.56 (-0.68%)

08/06/20 H.C. Wainwright
Karuna Therapeutics price target lowered to $130 from $140 at H.C. Wainwright
06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
NERV Minerva
$3.44 /

-0.005 (-0.15%)

07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/08/20 H.C. Wainwright
Minerva price target lowered to $10 from $20 at H.C. Wainwright
06/05/20 JMP Securities
Minerva reinstated with an Outperform at JMP Securities
06/01/20 JMP Securities
Minerva rating placed under review at JMP Securities
TRVN Trevena
$1.97 /

-0.12 (-5.76%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
ZGNX Zogenix
$23.90 /

-0.11 (-0.46%)

07/15/20 Stifel
Physician survey suggests Zogenix shares undervalued, says Stifel
06/29/20 Mizuho
Zogenix price target lowered to $55 from $64 at Mizuho
06/26/20 Stifel
FDA approval of Fintepla provides 'sigh of relief' for Zogenix, says Stifel
05/05/20 Piper Sandler
Zogenix price target lowered to $56 from $64 at Piper Sandler
ZGNX Zogenix
$23.90 /

-0.11 (-0.46%)

TRVN Trevena
$1.97 /

-0.12 (-5.76%)

NERV Minerva
$3.44 /

-0.005 (-0.15%)

KRTX Karuna Therapeutics
$82.23 /

-0.56 (-0.68%)

CRTX Cortexyme
$44.00 /

-0.65 (-1.46%)

CNCE Concert Pharmaceuticals
$10.10 /

-0.09 (-0.88%)

AQST Aquestive Therapeutics
$8.17 /

+0.09 (+1.11%)

ACAD Acadia
$38.91 /

-0.745 (-1.88%)

  • 12
    Aug
  • 04
    Mar
  • 06
    Feb
  • 28
    Jan
  • 23
    Jan
  • 13
    Dec
  • 21
    Nov
  • 18
    Sep
ZGNX Zogenix
$23.90 /

-0.11 (-0.46%)

TRVN Trevena
$1.97 /

-0.12 (-5.76%)

ZGNX Zogenix
$23.90 /

-0.11 (-0.46%)

TRVN Trevena
$1.97 /

-0.12 (-5.76%)

NERV Minerva
$3.44 /

-0.005 (-0.15%)

AQST Aquestive Therapeutics
$8.17 /

+0.09 (+1.11%)

ACAD Acadia
$38.91 /

-0.745 (-1.88%)

ZGNX Zogenix
$23.90 /

-0.11 (-0.46%)

TRVN Trevena
$1.97 /

-0.12 (-5.76%)

Conference/Events
JMP Securities to hold a virtual forum » 09:10
08/19/20
08/19
09:10
08/19/20
09:10
ACAD

Acadia

$39.66 /

+0.125 (+0.32%)

, AQST

Aquestive Therapeutics

$8.08 /

+0.51 (+6.74%)

, CNCE

Concert Pharmaceuticals

$10.19 /

-0.25 (-2.39%)

, CRTX

Cortexyme

$44.65 /

-0.35 (-0.78%)

, KRTX

Karuna Therapeutics

$82.79 /

-1.07 (-1.28%)

, NERV

Minerva

$3.44 /

-0.105 (-2.96%)

, TRVN

Trevena

$2.09 /

-0.18 (-7.95%)

, ZGNX

Zogenix

$24.01 /

-1.13 (-4.49%)

CNS Virtual Forum will be…

CNS Virtual Forum will be held on August 19-20.

ShowHide Related Items >><<
ZGNX Zogenix
$24.01 /

-1.13 (-4.49%)

TRVN Trevena
$2.09 /

-0.18 (-7.95%)

NERV Minerva
$3.44 /

-0.105 (-2.96%)

KRTX Karuna Therapeutics
$82.79 /

-1.07 (-1.28%)

CRTX Cortexyme
$44.65 /

-0.35 (-0.78%)

CNCE Concert Pharmaceuticals
$10.19 /

-0.25 (-2.39%)

AQST Aquestive Therapeutics
$8.08 /

+0.51 (+6.74%)

ACAD Acadia
$39.66 /

+0.125 (+0.32%)

ACAD Acadia
$39.66 /

+0.125 (+0.32%)

07/27/20 Canaccord
Acadia pullback a buying opportunity, says Canaccord
07/21/20 Oppenheimer
Acadia price target lowered to $42 from $53 at Oppenheimer
07/21/20 RBC Capital
Acadia price target lowered to $55 from $61 at RBC Capital
07/21/20 Citi
Acadia price target lowered to $63 from $69 at Citi
AQST Aquestive Therapeutics
$8.08 /

+0.51 (+6.74%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
CNCE Concert Pharmaceuticals
$10.19 /

-0.25 (-2.39%)

03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
01/22/20 Truist
Concert Pharmaceuticals price target raised to $30 from $25 at SunTrust
CRTX Cortexyme
$44.65 /

-0.35 (-0.78%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
KRTX Karuna Therapeutics
$82.79 /

-1.07 (-1.28%)

08/06/20 H.C. Wainwright
Karuna Therapeutics price target lowered to $130 from $140 at H.C. Wainwright
06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
NERV Minerva
$3.44 /

-0.105 (-2.96%)

07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/08/20 H.C. Wainwright
Minerva price target lowered to $10 from $20 at H.C. Wainwright
06/05/20 JMP Securities
Minerva reinstated with an Outperform at JMP Securities
06/01/20 JMP Securities
Minerva rating placed under review at JMP Securities
TRVN Trevena
$2.09 /

-0.18 (-7.95%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
ZGNX Zogenix
$24.01 /

-1.13 (-4.49%)

07/15/20 Stifel
Physician survey suggests Zogenix shares undervalued, says Stifel
06/29/20 Mizuho
Zogenix price target lowered to $55 from $64 at Mizuho
06/26/20 Stifel
FDA approval of Fintepla provides 'sigh of relief' for Zogenix, says Stifel
05/05/20 Piper Sandler
Zogenix price target lowered to $56 from $64 at Piper Sandler
ZGNX Zogenix
$24.01 /

-1.13 (-4.49%)

TRVN Trevena
$2.09 /

-0.18 (-7.95%)

NERV Minerva
$3.44 /

-0.105 (-2.96%)

KRTX Karuna Therapeutics
$82.79 /

-1.07 (-1.28%)

CRTX Cortexyme
$44.65 /

-0.35 (-0.78%)

CNCE Concert Pharmaceuticals
$10.19 /

-0.25 (-2.39%)

AQST Aquestive Therapeutics
$8.08 /

+0.51 (+6.74%)

ACAD Acadia
$39.66 /

+0.125 (+0.32%)

  • 12
    Aug
  • 04
    Mar
  • 06
    Feb
  • 28
    Jan
  • 23
    Jan
  • 13
    Dec
  • 21
    Nov
  • 18
    Sep
ZGNX Zogenix
$24.01 /

-1.13 (-4.49%)

TRVN Trevena
$2.09 /

-0.18 (-7.95%)

ZGNX Zogenix
$24.01 /

-1.13 (-4.49%)

TRVN Trevena
$2.09 /

-0.18 (-7.95%)

NERV Minerva
$3.44 /

-0.105 (-2.96%)

AQST Aquestive Therapeutics
$8.08 /

+0.51 (+6.74%)

ACAD Acadia
$39.66 /

+0.125 (+0.32%)

ZGNX Zogenix
$24.01 /

-1.13 (-4.49%)

TRVN Trevena
$2.09 /

-0.18 (-7.95%)

Earnings
Cortexyme reports Q2 EPS (60c), consensus (65c) » 08:09
08/17/20
08/17
08:09
08/17/20
08:09
CRTX

Cortexyme

$44.50 /

-0.58 (-1.29%)

Cash, cash equivalents,…

Cash, cash equivalents, and short and long-term marketable securities as of June 30, were $210.6M and includes approximately $117.6M of net proceeds raised in Cortexyme's private placement offering completed in February. Cortexyme expects current cash, cash equivalents and marketable securities will be sufficient to fund its operating and capital expenditures through 2022 and the completion of the GAIN Trial. "The participation of the medical community and patients in the GAIN study of atuzaginstat in mild to moderate Alzheimer's disease continues to be strong, and we're entering the final months of enrollment with key anticipated milestones on track," said Casey Lynch, Cortexyme's CEO, co-founder, and chair. "We are looking forward to the GAIN interim analysis before the end of this year, and we anticipate top-line data from the trial in the fourth quarter of 2021. At the same time, our research efforts continue to be productive and we are advancing additional molecules into IND-enabling studies, with the goal of expanding and adding value to our clinical pipeline in 2021. With a strong balance sheet and a talented team, we believe we are well positioned to potentially provide new therapeutic options to patients stricken with Alzheimer's and other neurodegenerative diseases."

ShowHide Related Items >><<
CRTX Cortexyme
$44.50 /

-0.58 (-1.29%)

CRTX Cortexyme
$44.50 /

-0.58 (-1.29%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
CRTX Cortexyme
$44.50 /

-0.58 (-1.29%)

  • 06
    Feb
Hot Stocks
Cortexyme reaches enrollment milestone of 500 patients in GAIN Trial for AD » 08:07
08/14/20
08/14
08:07
08/14/20
08:07
CRTX

Cortexyme

$45.08 /

+0.83 (+1.88%)

Cortexyme said in a…

Cortexyme said in a release, "Cortexyme announced that enrollment in its GAIN Trial for Alzheimer's disease , or AD, has reached 500 patients toward the study's previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme's lead investigational medicine, in patients with mild to moderate AD. The GAIN Trial's protocol includes an interim analysis on the study's co-primary cognitive and functional endpoints after approximately 300 patients reach 24 weeks of treatment; this interim analysis is expected to occur before year-end 2020. Top-line results of the GAIN Trial's final analysis, to be performed once all study subjects complete the one-year study, are expected in Q4 2021."

ShowHide Related Items >><<
CRTX Cortexyme
$45.08 /

+0.83 (+1.88%)

CRTX Cortexyme
$45.08 /

+0.83 (+1.88%)

06/24/20 H.C. Wainwright
Cortexyme initiated with a Buy at H.C. Wainwright
06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Jefferies
Jefferies starts Cortexyme with Buy on Alzheimer's potential
06/02/20 Jefferies
Cortexyme initiated with a Buy at Jefferies
CRTX Cortexyme
$45.08 /

+0.83 (+1.88%)

  • 06
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.